24/08/2026
👁️ MYOPIA MANAGEMENT — KEY CLINICAL POINTS
Myopia control ≠ simply prescribing a new spectacle power.
It refers to evidence-based interventions aimed at slowing myopia progression and/or axial elongation, with treatment efficacy ideally monitored using cycloplegic refraction + axial length. (Myopia Institute -)
🔹 Key risk factors
Younger age at myopia onset → generally faster progression
Parental myopia
Reduced outdoor exposure
High near-work demand, particularly prolonged continuous near work and very close working distance (Myopia Institute -)
🔹 Evidence-based management options
Myopia-control spectacle lenses — peripheral defocus / contrast-reduction designs
Dual-focus / multifocal soft contact lenses
Orthokeratology (Ortho-K)
Low-dose atropine
Combination therapy in selected progressing cases
Increasing evidence is also emerging for light-based interventions, although protocols and long-term evidence continue to evolve. (Myopia Institute -)
🔹 Clinical monitoring matters
Don't judge treatment success from refractive error alone.
👉 Track cycloplegic refraction + axial length where appropriate.
👉 Monitor treatment adherence, visual function, ocular health and progression over time. (Myopia Institute -)
🔹 Lifestyle counselling
Encourage:
Regular outdoor time 🌳
Appropriate reading distance
Breaks during prolonged near work/screen use
Full-time wear of the prescribed myopic correction unless clinically contraindicated. (Myopia Institute -)
Clinical takeaway:
Early identification + accurate baseline assessment + evidence-based intervention + longitudinal monitoring = effective myopia management.
Sources: International Myopia Institute (IMI) 2025 Interventions for Controlling Myopia Onset and Progression; IMI 2025 Clinical Management/Instrumentation; IMI Myopia Correction, Myopia Control and Myopia Management consensus. (Myopia Institute -)
International Myopia Institute – Clinical Summaries